PURPOSE: To investigate the novel application of tissue microarray (TMA) technology to corneal disease and to report altered protein expression of senescence-associated cyclin-dependent kinase inhibitors p21 and p16 in Fuchs endothelial corneal dystrophy (FECD). METHODS: A TMA including 208 cores was generated from paraffin-embedded tissues, including corneal buttons of 50 FECD and 5 keratoconus patients retrieved after penetrating keratoplasty, 10 autopsy globes with nonpathologic corneas, and nonocular control specimens. TMA sections were immunolabeled for p21 and p16 and analyzed using a 9-grade scoring system (0-8). Result validation was performed by immunolabeling of individual whole tissue sections. Corneal endothelial p21 and p16 expression levels in FECD specimens compared with controls served as main outcome measures. RESULTS: TMA immunohistochemical analysis disclosed increased endothelial expression levels of nuclear p21 in FECD specimens (P < 0.05) and an altered endothelial p16 expression pattern. Immunolabeling of whole tissue sections showed statistically significant endothelial overexpression of both proteins (p21 and p16, P < 0.05). CONCLUSIONS: The present study introduces TMA technology as a valuable tool for molecular high-throughput profiling of corneal tissues. It demonstrates p21 and p16 overexpression in the corneal endothelium of genetically undifferentiated FECD patients supporting a role of cellular senescence in the pathogenesis of FECD.
PURPOSE: To investigate the novel application of tissue microarray (TMA) technology to corneal disease and to report altered protein expression of senescence-associated cyclin-dependent kinase inhibitors p21 and p16 in Fuchs endothelial corneal dystrophy (FECD). METHODS: A TMA including 208 cores was generated from paraffin-embedded tissues, including corneal buttons of 50 FECD and 5 keratoconus patients retrieved after penetrating keratoplasty, 10 autopsy globes with nonpathologic corneas, and nonocular control specimens. TMA sections were immunolabeled for p21 and p16 and analyzed using a 9-grade scoring system (0-8). Result validation was performed by immunolabeling of individual whole tissue sections. Corneal endothelial p21 and p16 expression levels in FECD specimens compared with controls served as main outcome measures. RESULTS:TMA immunohistochemical analysis disclosed increased endothelial expression levels of nuclear p21 in FECD specimens (P < 0.05) and an altered endothelial p16 expression pattern. Immunolabeling of whole tissue sections showed statistically significant endothelial overexpression of both proteins (p21 and p16, P < 0.05). CONCLUSIONS: The present study introduces TMA technology as a valuable tool for molecular high-throughput profiling of corneal tissues. It demonstrates p21 and p16 overexpression in the corneal endothelium of genetically undifferentiated FECDpatients supporting a role of cellular senescence in the pathogenesis of FECD.
Authors: A Seluanov; V Gorbunova; A Falcovitz; A Sigal; M Milyavsky; I Zurer; G Shohat; N Goldfinger; V Rotter Journal: Mol Cell Biol Date: 2001-03 Impact factor: 4.272
Authors: Imran A Bhutto; Sahng Y Kim; D Scott McLeod; Carol Merges; Naomi Fukai; Bjorn R Olsen; Gerard A Lutty Journal: Invest Ophthalmol Vis Sci Date: 2004-05 Impact factor: 4.799
Authors: J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi Journal: Nat Med Date: 1998-07 Impact factor: 53.440
Authors: Angela N Sheerin; S Kaye Smith; Katrin Jennert-Burston; Amy J Brook; Marcus C Allen; Badr Ibrahim; Dawn Jones; Corrin Wallis; Katrin Engelmann; William Rhys-Williams; Richard G A Faragher; David Kipling Journal: Aging Cell Date: 2011-12-29 Impact factor: 9.304
Authors: Mario Matthaei; Jianfei Hu; Laura Kallay; Charles G Eberhart; Claus Cursiefen; Jiang Qian; Eva-Maria Lackner; Albert S Jun Journal: Invest Ophthalmol Vis Sci Date: 2014-01-09 Impact factor: 4.799
Authors: Mario Matthaei; Jianfei Hu; Huan Meng; Eva-Maria Lackner; Charles G Eberhart; Jiang Qian; Haiping Hao; Albert S Jun Journal: Invest Ophthalmol Vis Sci Date: 2013-03-15 Impact factor: 4.799
Authors: Mario Matthaei; Angela Y Zhu; Laura Kallay; Charles G Eberhart; Claus Cursiefen; Albert S Jun Journal: Exp Eye Res Date: 2014-10-11 Impact factor: 3.467
Authors: Franziska Bucher; Werner Adler; Helmar C Lehmann; Deniz Hos; Philipp Steven; Claus Cursiefen; Ludwig M Heindl Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-05-30 Impact factor: 3.117